Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas

Complete title: H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas

Research Study Number PNOC007
Principal Investigator Sarah Leary
Phase I

Research Study Description

This is a two cohort Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC).

This study will assess the safety of repeated administration of the H3.3K27M specific vaccine in HLA-A2+ children and young adults with H3.3K27M DIPGs and other gliomas.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number PNOC007
Contact Sarah Leary
Telephone 206/987-6661

Keywords: Glioma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Immunotherapy; Diffuse Intrinsic Pontine Glioma (DIPG)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials